The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | ECHELON-2: brentuximab vedotin and CHP for CD30-positive T-cell lymphomas
In this interview, Stephen Ansell, MD, PhD, of the Mayo Clinic, Rochester, MI, discusses the Phase III ECHELON-2 trial (NCT01777152) comparing the efficacy and safety of brentuximab vedotin in combination with CHP vs. the standard of care (CHOP) in patients with CD30-positive T-cell lymphomas. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Ansell reveals the improved outcomes for the patients receiving the brentuximab vedotin regimen, and importantly an improvement in OS; a practice changing result.
